Intervir is developing first in class antiviral therapeutics that specifically target an essential mechanism for budding, release and dissemination of viruses. The target for these therapeutics and our initial clinical development efforts are for the treatment of deadly hemorrhagic viruses including Ebola, Marburg and Lassa viruses. The molecular target for Intervir compounds is found in a wide array of viruses and our therapeutics will have broad-antiviral applicability.